title: Autologous BMT for post-remission therapy in adult ALL: an immunological approach. For The French Group of Therapy of Adult ALL.
abstract: Among patients included in the multicentric trial ALL87, 95 patients were randomly allocated to purged ABMT arm for post-remission therapy. Immunological phenotyping performed in patients at diagnosis allowed to assigned 51 patients (54%) to the B lineage and 34 patients (36%) to the T lineage. Only 64 patients (67%) actually received ABMT mainly because of early relapses. Fifty-two patients were depleted according to the protocol: 25 B-ALL were depleted with CD10+CD19 mAbs, 19 T-ALL with CD2+CD5+CD7 mAbs and 8 patients received an Asta-Z purged BMT. Among the 12 remaining patients, 4 received Asta-Z purged BMT and 8 an unpurged one. Using an intention to treat analysis, overall survival and event free survival were similar to results observed in chemotherapy group. This study emphasizes the importance of a precise phenotyping at ALL diagnosis which allows specific immunologic bone marrow purging for ABMT.
authors.forename: E
authors.initials: E
authors.lastname: Racadot
authors.forename: C
authors.initials: C
authors.lastname: Sebban
authors.forename: C
authors.initials: C
authors.lastname: Boucheix
authors.forename: B
authors.initials: B
authors.lastname: David
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: J
authors.initials: J
authors.lastname: Rieffers
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
authors.forename: X
authors.initials: X
authors.lastname: Troussard
authors.forename: P
authors.initials: P
authors.lastname: Hervé
mesh_terms: D000293:Adolescent; D000328:Adult; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D006801:Humans; D016130:Immunophenotyping; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*